Thickening of the heel-pad associated with long-term Dilantin therapy.
Thickening of the heel-pad is added to the list of side effects of Dilantin medication. Any measurement above 20 mm. in a white patient was considered abnormal. Only 1 of 43 controls measured above this value, while in patients receiving Dilantin the percentage of patients manifesting abnormally thickened hell-pads increased steadily with length of treatment; after 10 years 7 out of 12 patients showed this change. Dilantin medication should be included in the differential diagnosis of heel-pad thickening.
D000886:Anthropometry / Q000379:methods; D003238:Connective Tissue / Q000187:drug effects*; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005534:Foot Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging; D006365:Heel / Q000000981:diagnostic imaging / Q000187:drug effects*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D010672:Phenytoin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011859:Radiography; D012737:Sex Factors; D013679:Technology, Radiologic
D010672:Phenytoin